VANGUARD GROUP INC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 1:17 pm Sale | 2026-03-13 | 13G | SPYRE THERAPEUTICS, INC SYRE | VANGUARD GROUP INC | 0 0.000% | -3,066,586 (Position Closed) | Filing |
| 2025-07-29 2:40 pm Purchase | 2025-06-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | VANGUARD GROUP INC | 3,066,586 5.080% | 3,066,586 (New Position) | Filing |